AstraZeneca’s COPD drug scores two late-stage trial wins as full data boosts blockbuster hopes
The biologic cut moderate and severe flare-ups in late-stage trials, and AstraZeneca said peak annual sales could top $5 billion.
- On Tuesday, AstraZeneca released results from two late-stage trials of tozorakimab, which reduced moderate and severe COPD flare-ups by 29% and 34% in former smokers. The biologic is under Food and Drug Administration priority review, with approval expected in the first quarter of 2027.
- AstraZeneca designed tozorakimab to inhibit two distinct IL-33 pathways, addressing inflammation, mucus production, and airway damage. This dual-pathway mechanism differentiates the biologic from previous unsuccessful IL-33 treatments that faced investor skepticism.
- Trial data showed a 23% flare-up reduction for patients with low eosinophil counts, a group currently lacking biologic options. Ruud Dobber, president of AstraZeneca's biopharmaceuticals unit, said, "We truly believe that a large population of COPD patients can benefit from this new medicine."
- AstraZeneca raised its peak annual sales forecast for tozorakimab to more than $5 billion, supporting the company's $80 billion revenue target by 2030. CEO Soriot remarked, "Tozorakimab is a product nobody thought would work," reflecting initial industry skepticism.
- Beyond COPD, AstraZeneca is testing tozorakimab in a Phase 2 trial for severe asthma and a Phase 3 study for severe viral lower respiratory tract disease. These ongoing trials suggest a broader strategy to leverage the platform across multiple respiratory conditions.
9 Articles
9 Articles
New biologic therapy significantly reduces COPD flare-ups in trials
Two international clinical trials led in part by researchers at the University of Pittsburgh School of Medicine found that the investigational biologic therapy tozorakimab significantly reduced chronic obstructive pulmonary disease (COPD) flare-ups among patients already receiving standard treatment for the disease compared to patients only receiving standard treatment.
AstraZeneca : Tozorakimab demonstrated statistically significant and highly clinically meaningful reduction in COPD exacerbations in OBERON and TITANIA Phase III trials
Tozorakimab showed clinically meaningful benefits across blood eosinophil thresholds Full results published in the New England Journal of Medicine and presented at the European...
AstraZeneca's COPD drug scores two late-stage trial wins as full data boosts blockbuster hopes
The full data reinforces hopes that the drug could be a breakthrough COPD treatment and reach AstraZeneca's peak annual sales forecast of more than $5 billion.
Coverage Details
Bias Distribution
- 50% of the sources lean Left, 50% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
